Imagion Biosystems Limited
IBXXF
$0.01
-$0.025-71.43%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -75.94% | -75.38% | 133.71% | 127.99% | 51.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -75.94% | -75.38% | 133.71% | 127.99% | 51.23% |
| Cost of Revenue | -97.76% | -97.71% | -85.13% | -85.50% | 63.45% |
| Gross Profit | -22.35% | -20.52% | 184.62% | 182.52% | 27.76% |
| SG&A Expenses | -84.91% | -84.55% | -64.56% | -65.44% | 18.22% |
| Depreciation & Amortization | -98.72% | -98.67% | -35.14% | -36.71% | 0.10% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -90.29% | -90.06% | -68.13% | -68.91% | 28.97% |
| Operating Income | 103.87% | 103.96% | 87.40% | 87.71% | -13.19% |
| Income Before Tax | 88.73% | 88.46% | 80.39% | 80.88% | -17.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 88.73% | 88.46% | 80.39% | 80.88% | -17.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 88.73% | 88.46% | 80.39% | 80.88% | -17.31% |
| EBIT | 103.87% | 103.96% | 87.40% | 87.71% | -13.19% |
| EBITDA | 105.07% | 108.33% | 92.00% | 92.20% | -0.03% |
| EPS Basic | 93.50% | 93.32% | 83.04% | 83.44% | 0.21% |
| Normalized Basic EPS | 93.62% | 93.33% | 83.10% | 83.48% | 0.33% |
| EPS Diluted | 93.50% | 93.32% | 83.04% | 83.44% | 0.21% |
| Normalized Diluted EPS | 93.62% | 93.33% | 83.10% | 83.48% | 0.33% |
| Average Basic Shares Outstanding | 75.03% | 75.03% | 15.50% | 15.50% | 17.59% |
| Average Diluted Shares Outstanding | 75.03% | 75.03% | 15.50% | 15.50% | 17.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
